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IN this work we have studied the acute phase protein
response and degranulation of polymorphonuclear
leukocytes in vivo in the rat after a slow interleukin-l[
stimulation. A total dose of ltg, 2 tg, 4 tg and 0 tg
(controls with only vehicle) of interleukin-l[ was re-
leased from osmotic minipumps over a period of 7 days.
The pumps were implanted subcutaneously. A cystic for-
mation was formed around the pumps that contained
interleukin-l[ whereas no tissue reaction was seen
around pumps containing only vehicle. Besides
flbroblasts the cyst wall contained numerous poly-
morphonuclear leukocytes which were positively
stained for cathespin G. 2-macroglobulin, xl-inhtbitor-3,
xl-proteinase inhibitor, albumin and C3 were measured
by electroimmunoassay and all showed plasma concen-
tration patterns that were dose-dependent to the amount
of interleuktn-l released. Fibrinogen in plasma was el-
evated in the control group but showed decreased plasma
values with higher doses of interleukin-l[$ released. All
animals showed increased plasma levels of cathespin G
but the lowest levels for cathespin G were seen for the
highest interleukin-l[ dose released. It was clearly seen
that a slow continuous release of interleukin-l[ in vtvo
caused an inflammatory reaction. Plasma levels for the
proteins analysed allshowed a similar pattern, namely an
initial increase or decrease of plasma concentration fol-
lowed by a tendency to normalization of plasma values.
It was concluded that a long-term interleukin-l[ release
could not sustain the acute phase protein response
elicited by the initial interleukin-l[ release.
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Introduction
An inflammatory reaction may be defined as ’the
reaction of vascularized living tissue to local injury’.
The local tissue injury may be caused by mechanical
trauma, radiation, microorganisms (infection),
neoplasia, burn injury, chemical irritation, etc. Re-
gardless of how the local tissue injury is caused, the
vascularized living tissue will react mainly in a uni-
form way. This is probably due to the different
specialized inflammatory cells and their capability to
communicate. By inflammatory mediators and cellu-
lar receptors, cells are signalling and receiving signals
in a huge complex network. Interleukin-1 (IL-1)" is a
well-known inflammatory mediator holding a central
position in the inflammatory reaction. It has the
capability to induce an acute phase protein response
from the liver and to induce degranulation of
polymorphonuclear leukocytes (PMNs) in vivo. Sev-
eral plasma proteins are increased or decreased as a
part of the acute phase response and this acute phase
protein response differs from species to species.
Two proteinase inhibitors, namely l-
antichymotrypsin and l-proteinase inhibitor (oqPI),
are among the strongest reacting acute phase pro-
teins in humans. By forming complexes with PMN
cathepsin G and elastase they inhibit these two PMN
proteases. In the rat ot2-macroglobulin ({2M) and {l-
inhibitor-3 (RlI3) are marked acute phase proteins.
The objective of the present work was to investigate
the effects of a slow continuous stimulation of IL-1
on some acute phase proteins and PMNs
degranulation in vivo.
Materials and Methods
Assays: Rat cathepsin G was measured by a specific
enzyme-linked immunosorbent assay (ELISA) as
described. Rat 0,.M, 01I, C fibrinogen, 0qPI and
albumin were measured by electroimmunoassay.
Antisera against rat 0t,.M and 1I were prepared as
described. 8,9 Rabbit anti-rat C3 and rabbit anti-rat
fibrinogen were obtained from Cappel, USA and
rabbit anti-rat IPI and rabbit anti-rat albumin were
() 1994 Rapid Communications of Oxford Ltd Mediators of Inflammation. Vol 3. 1994 425P. Bj(Jrk, T. Gudmundsson and K. Ohlsson
a gift from Dr C-B. Laurell (Department of Clinical
Chemistry, Malm6 General Hospital). Enzymatic ac-
tivity of cathepsin G was determined using the
substrate Suc-Ala-Ala-Pro-Phe-pNA (SucAAPP)
(Sigma) as described.1
Immunohistochemistr)2. Formalin fixed tissue sec-
tions were embedded in paraffin, cut and mounted
on glass slides. Staining was done by the ._=
peroxidase-antiperoxidase method as described. 11
Animal experiments: Female Wistar rats (Mllegaard .
Avelslaboratorium A/S, DK-4623 Skensved, Den- " mark) weighing 230 g were used. The animals were
anaesthetized by an intraperitoneal injection of
Mebumal
(R) and then the back of the animals were
shaved and disinfected. Through a small incision
(approximately 15 mm in length) in the skin an
osmotic minipump ’Model 2001’ (Alzet) was im-
planted subcutaneously. The flow rate of the pump
was I l.tl/h for 7 days. After implantation the rats were
allowed to wake up. Four groups of rats containing
five animals each received pumps with different
amounts of recombinant human IL-I (rhlL-lJ]), 0 l.tg
(controls), 1 l.tg, 2 l.tg and 4 l.tg. In addition, two rats
received minipumps subcutaneously containing 4 l.tg
IL-1. After 3 days these two latter pumps were re-
moved and reimplanted in two new rats which were
followed for 3 days in an attempt to test the func- .-
tional stability of rhIL-l during the experimental ’,
conditions. The rhIL-1 was prepared by "
recombinant DNA technology in Escherichia coli "
(Synergen Inc., USA). The protein was diluted to
appropriate concentrations in sterile filtered phos-
phate buffered saline, pH 7.4 (Dulbecco) with 0.2%
(w/v) bovine serum albumin (Sigma) and filled into
the pumps. Blood samples of approximately 0.4 ml
were taken from the tail into tubes containing EDTA.
Plasma was immediately prepared and frozen at
-70C. Samples were collected at time 0, just
before the implantation of the osmotic minipumps
and thereafter every 24 h for 7 days. After 7 days
the animals were sacrificed with an overdose of
Mebumal
(R) and the eventual cystic formation and
cystic fluid around the pumps were collected. The
cystic formations were fixed in phosphate buffered
formalin until paraffin embedded and the cystic
fluids were centrifuged and frozen at-70C until
analysed. During the whole experimental time the
animals had free access to water and standard pellet
FIG. 1. Using subcutaneously implanted osmotic minipumps rats were
stimulated by a slow release of different amounts of IL-11 diluted in 0.2%
BSA (w/v) in PBS. One group received only vehicle (control group), while
three other groups received 6 ng/h IL-11, 12 ng/h IL-1 I and 24 ng/h IL-11,
respectively. Here results from the control group (O-O) and the group that
received 24 ng/h IL-11 (e-e) are presented. Blood samples were taken
from the tail just before implantation of the osmotic pump and thereafter for
7 days. Values are given as mean values standard error of the mean. All
groups contained five rats. %M (a), %PI (b), %1 (c), albumin (d), C (e) and
fibrinogen (f) were measured by EIA. Plasma cathepsin G (g) was meas-
ured by a specific ELISA.
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food. The animal experiments were sanctioned by
the local ethical committee for animal experiments.
Results
Tissue reactions: The rats did not show any outer
signs of discomfort throughout the experiment. At
autopsy a cystic formation was seen around osmotic
minipumps containing IL-1 irrespective of dose,
whereas no tissue reaction was seen around pumps
without IL-1 (controls). No enzymatic activity of
cathepsin G as measured by activity against SucAAPP
could be detected in the cystic fluid. Cathepsin G
concentration in the fluids was measured by a..spe-
cifi ELISA and mean value + SEM in the groups
were: 1 l.tg IL-1 179 + 7 l.tg/1, 2 l.tg IL-1 179 +
13 lg/1 and 4 btg/1 176 + 8 l.tg/1.
Acutephase proteins: 2M, 0tlI3, C3, fibrinogen, :IPI
and albumin were all measured by electro-
immunoassay. ,M was not detectable in plasma at
time 0, just before the implantation of the osmotic
minipumps, when measured by electroimmuno-
assay. Detectable amounts were seen after one day
and throughout the observation period with peak
values on day 1 and 2 (Fig. la). A dose-response
pattern was seen for ,.M. Plasma 0tlPI showed the
highest values on day 2 with values ranging from 140
to 160% of the starting levels (Fig. lb). The values
then gradually decreased during the experimental
time. glI plasma levels decreased with the greatest
decrease in the group that received 4 I.tg IL-1 (Fig.
lc). Normal plasma level was not totally restored
during the observation period. The same pattern was
seen for albumin (Fig. ld). Plasma values for C3 were
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increased during the whole experimental time (Fig.
le). Rats treated with the highest doses showed a
value of 180% on day 7 compared with the starting
value. After an initial increase of fibrinogen in the
controls the values thereafter decreased. However, in
the two groups receiving the largest amounts of IL-
l an almost immediate decrease in plasma values
were seen (Fig. lf). An equal increase in o2M plasma
levels were seen in the two rats that received a pump
formerly implanted for 3 days in two other rats
(Fig. 2).
Plasma cathepsin G in IL-1 stimulated rats: Plasma
levels of cathepsin G at time 0 were below the
detection level 1.5 btg/1 of the specific ELISA used.
Irrespective of the IL-1 dose administered, a biphasic
curve was seen in plasma levels (Fig. lg).
Immunohistochemistr)2. In sections from the cystic
formation with adjacent skin numerous inflammatory
cells were seen in the dense wall of fibroblasts (Fig.
3a). Approximately half of the inflammatory cells
were stained for cathepsin G.
Discussion
IL-1 is an important cytokine released in the inflam-
matory process. There are two forms of IL-1, IL-I
0 4 6
Time (days)
FIG. 2. Osmotic minipumps containing 41g IL-I was implanted subcuta-
neously in two rats, Plasma samples were taken prior to implantation and
thereafter daily for 3 days, After 3 days the pumps were removed and
implanted in two new rats. Blood samples were taken prior to implantation
of the pumps and thereafter daily for 4 days. Plasma levels of%M are given
(-). The arrow indicates the time for reimplantation in new rats.
and IL-I. They both act on the same receptors
12 and
they also elicit the same cellular response. Recently
a specific IL-1 receptor antagonist (IL-lra) has been
isolated in its native form and also cloned.1-15 The
importance of IL-1 in the acute inflammatory process
FIG. 3. Section from cyst formation formed around osmotic minipumps containing IL-11. (a) Hematoxylin eosin stained tissue, magnification x 500. Numerous
inflammatory cells are seen in the wall of the cyst. (b) Tissue only immunohistochemically stained with rabbit anti-rat PMN cathepsin G, magnification x 500.
Note PMNs containing cathepsin G. (c) Tissue incubated with normal rabbit serum as control.
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may be illustrated by survival of rabbits receiving a
normally lethal endotoxin dose after treating the
animals with intravenous injections of IL-lra. 16 Al-
though the effects of IL-1 are well documented most
of the knowledge has come from studies in vitro and
studies in vivo may be a valuable complement for the
understanding of the pathophysiological role of IL-1.
In this work we have studied the effects on the
acute phase protein response and the degranulation
of PMNs by a slow IL-1 release stimulation over a
period of 7 days. Even with only vehicle present in
the mini osmotic pumps (control group) a clear
inflammatory reaction could be seen for the acute
phase proteins. In these animals fibrinogen, 0qPI and
(xiM all showed elevation of plasma values for the
first 2 days but these values decreased over time
towards the origin values. C3 in plasma increased to
125% after 2 days and thereafter the plasma values
stayed at this level throughout the observation time.
Both albumin and zlI showed decreased plasma
values over the whole observation period. Cathepsin
G was released to the bloodstream as measured by
elevated plasma levels from the second day to the
seventh day. All these findings are in agreement with
an inflammatory reaction due to the trauma from the
operative procedure. No local tissue reaction was
seen around the implanted pumps only containing
vehicle, indicating that no greater irritation was
caused to the surrounding tissue.
When IL-1 was released from the mini osmotic
pumps a more pronounced acute phase protein re-
action was seen. For 0t,.M, zlPI and C3 there was a
dose-dependent pattern seen in the elevated plasma
values. Also for the negative acute phase protein
reactants albumin and (Eli a dose-dependent pattern
could be detected. Fibrinogen is a positive acute
phase protein reactant in humans reaching a maxi-
mum plasma concentration approximately on the
third day after tissue injury.
17 When increasing
amounts of IL-1 were given the plasma levels of
fibrinogen decreased over time and the positive
acute phase response was changed into a negative
acute phase response. How this change in acute
phase answer is mediated is not known but our
results are in agreement with a study by De Jong
et all8
The data so far discussed clearly show that the
tissue injury caused by implantation of the osmotic
minipump is causing an acute phase protein re-
sponse and that this response is enhanced by the
stimulation of IL-I. The general plasma protein
levels over the experimental time showed an initial
peak or dip followed by a tendency to return to
original values in spite of the continuous release of
IL-1 over the whole experimental time. To examine
that the IL-1 in the pumps did not lose its biological
activity we removed pumps from two rats and
reimplanted them in two new rats. The same reaction
pattern for otaM was seen in all these four rats clearly
indicating that IL-1 did not lose its biological activity
over the experimemal time. Therefore, an explana-
tion for these results may be that the initial release of
IL-1 also provokes a reaction to counteract effects of
IL-1. This effect could be mediated by an induction
of IL-1 receptor antagonist. IL-1 has the capability to
induce IL-619 production which in turn may induce
IL-1 receptor antagonist production as recently
shown,a Another explanation could be inactivation
of IL-1 in the immediate surrounding of the pumps
by proteolytic enzymes. In this study we showed
high levels of cathepsin G in the cystic formations.
However, no enzymatic activity against the cathepsin
G substrate SucAAPP was detected indicating the
measured levels of cathepsin G to be enzymatically
inactive probably by inhibition by protease inhibitors
or by autodigestion.
Around the osmotic mini pumps cystic formations
containing a serous liquid were formed when the
pumps contained IL-1, while in pumps with only
vehicle no cystic formation was seen. This reaction
has previously been described by Lewis et aL2 and
Dunn et aL"" It is known that IL-1 has the capability
to stimulate fibroblasts2 and IL-1 is therefore sug-
gested to be one of the major mediators of skin
inflammation. It is likely that the cystic formation
seen is a result of such a stimulation. Cathepsin G
was measured in the liquids and values were
approximately 170 g/1 irrespective of the IL-1 dose
given. In the wall of the cystic formation numerous
inflammatory cells could be seen in histological
sections. About 50% of the cells were stained for
cathepsin G which may be a source for the high
concentrations of cathepsin G seen in the fluid.
Cathepsin G and other proteases like elastase from
PMNs have the capability to degrade proteins and
cathepsin G and elastase has been shown to be able
to degrade TNFot and TNF but not IL-1R. ’4 The
presence of proteases in this cystic formation
surrounding the minipump may influence the IL-1
released.
While the acute phase proteins showed a dose-
dependent response to the amount of IL-1 adminis-
tered cathepsin G plasma levels did not show any
tendency to a dose-dependent release. These data
are in contrast to our previous study where cathepsin
G plasma levels showed a dose-dependent pattern to
a single injection of IL-1. We have no obvious
explanation for the difference in these results. When
proteolytic enzymes like cathepsin G are released to
the bloodstream, complexes with inhibitors are
formed. These complexes are then removed from the
circulation by the liver. This removal is mediated by
specific receptors on the endothelial cells in the
liver.’s It may be speculated that the capacity of the
liver to remove complexes from the bloodstream may
be improved due to the long standing IL-1
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stimulation and thus the lowest cathepsin G plasma
concentrations are measured in the highest IL-1
dose given.
To summarize, we have found the initial release of
IL-1 to be the most important stimulation regarding
the acute phase protein response from the liver.
Although the IL-1 release was continued for 7 days
the acute phase protein levels in plasma approached
towards normal values after the increase/decrease
during the first 2 days.
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